Immunological analysis method, analysis kit, and monoclonal antibody for C-terminal telopeptides of type I collagen.

Abstract

The present invention addresses the problem of providing: an immunological analysis method using a monoclonal antibody, enabling analysis of ICTP without requiring a special facility; and a kit including the monoclonal antibody.　Said problem can be solved by an immunological analysis method that is for a type-I collagen C-terminal telopeptide in a biological sample and that comprises bringing the type-I collagen C-terminal telopeptide into contact with a monoclonal antibody that recognizes, as an epitope, an amino acid sequence of GFDFSFLP (SEQ ID NO: 1).

Description

Technical Field

[0001] The present invention relates to an immunological analysis method for type I collagen C-terminal telopeptide. The present invention also relates to an analysis kit for analyzing type I collagen C-terminal telopeptide. The present invention also relates to a monoclonal antibody that recognizes a specific epitope in type I collagen C-terminal telopeptide.

Background Art

[0002] Type I collagen C-terminal telopeptide (hereinafter sometimes referred to as ICTP) is a peptide produced during the degradation process of type I collagen, which is the main component of the bone matrix. ICTP is produced when type I collagen is cleaved by MMP (matrix metalloproteinase).

[0003] ICTP is one of the bone resorption markers. The ICTP concentration in blood is significantly higher in cases of bone metastasis of malignant tumors, particularly breast cancer, prostate cancer, or lung cancer, compared to cases without bone metastasis. This is thought to be because ICTP production progresses due to the degradation of collagen molecules by osteoclasts by MMP that is highly expressed in the environment where bone metastasis of malignant tumors has occurred. Therefore, the ICTP concentration in blood is considered useful as an indicator for assisting in the diagnosis of bone metastasis of malignant tumors or for the therapeutic effect.

[0004] As a reagent for measuring ICTP, pyridinoline ICTP (Fuji Rebio Co., Ltd.) is used. However, this measurement reagent employs a radioimmunoassay using a polyclonal antibody. Therefore, in order to use this measurement reagent, special facilities for handling radioisotopes are required. Thus, the development of a method and reagent for analyzing ICTP without requiring special facilities has been desired.

[0005] Patent Document 1 describes the preparation of an anti-ICTP polyclonal antibody using a sequence in ICTP as an antigen. It also describes the analysis of ICTP using this anti-ICTP polyclonal antibody. However, a monoclonal antibody capable of measuring ICTP, and an analytical method using a monoclonal antibody, are not disclosed. Monoclonal antibodies are generally more specific than polyclonal antibodies and have lower cross-reactivity to substances with structures similar to the substance being detected. [Prior art documents] [Patent Documents]

[0006] [Patent Document 1] Special publication H8-509294 [Overview of the Initiative] [Problems that the invention aims to solve]

[0007] The object of the present invention is to provide a method using a monoclonal antibody and a kit containing the monoclonal antibody that can analyze ICTP without requiring special facilities. [Means for solving the problem]

[0008] The inventors diligently studied to solve the above problems. They discovered that the above problems could be solved by using a monoclonal antibody that recognizes the amino acid sequence shown by GFDFSFLP (SEQ ID NO: 1) as an epitope, and thus completed the present invention. Specifically, the present invention is as follows: <1> An immunological analysis method for type I collagen C-terminal telopeptides in biological samples, Contacting the aforementioned type I collagen C-terminal telopeptide with a monoclonal antibody that recognizes the amino acid sequence represented by GFDFSFLP (SEQ ID NO: 1) as an epitope. Immunological analytical methods, including [specific examples]. <2> The monoclonal antibody does not recognize the amino acid sequence indicated by FDFSFLP (SEQ ID NO: 2) as an epitope. <1> The immunological analysis method described below. <3> A labeling substance is directly or indirectly bound to the monoclonal antibody. <1> or <2> The immunological analysis method described below. <4> The labeling substance is a metal complex, an enzyme, insoluble particles, or a metal colloid. <3> The immunological analysis method described below. <5> step of measuring the signal originating from the labeling substance. Further including, <3> or <4> The immunological analysis method described below. <6> The biological sample is blood, plasma, or serum. <1> ~ <5> An immunological analysis method described in any of the following. <7> The aforementioned biological sample is from a subject who has breast cancer, prostate cancer, or lung cancer, and whose cancer has metastasized to the bone. <1> ~ <6> An immunological analysis method described in any of the following. <8> The methods include electrochemiluminescence immunoassay, latex immunoturbidimetry, immunochromatography, or ELISA. <1> ~ <7> An immunological analysis method described in any of the following. <9> The aforementioned biological sample contains type I collagen C-terminal telopeptide at a concentration of 0.1 ng / mL to 1 μg / mL. <1> ~ <8> An immunological analysis method described in any of the following. <10> The process further includes comparing the signal with a threshold. <5> ~ <9> An immunological analysis method described in any of the following. <11> This is an analysis kit for type I collagen C-terminal telopeptides in biological samples, An analysis kit containing a monoclonal antibody that recognizes the amino acid sequence indicated by GFDFSFLP (SEQ ID NO: 1) as an epitope. <12> The monoclonal antibody does not recognize the amino acid sequence indicated by FDFSFLP (SEQ ID NO: 2) as an epitope. <11> The analysis kit described above. <13> The biological sample is blood, plasma, or serum. <11> or <12> The analysis kit described above. <14> The aforementioned biological sample is from a patient who has breast cancer, prostate cancer, or lung cancer and has bone metastases. <11> ~ <13> An analysis kit as described in any of the following. <15> For use in electrochemiluminescence immunoassay, latex immunoturbidimetry, immunochromatography, or ELISA, <11> ~ <14> An analysis kit as described in any of the following. <16> The aforementioned biological sample contains type I collagen C-terminal telopeptide at a concentration of 0.1 ng / mL to 1 μg / mL. <11> ~ <15> An analysis kit as described in any of the following. <17> A monoclonal antibody that recognizes the amino acid sequence shown by GFDFSFLP (SEQ ID NO: 1) as an epitope. <18> The amino acid sequence shown by FDFSFLP (SEQ ID NO: 2) is not recognized as an epitope. <17> The monoclonal antibody described above. [Effects of the Invention]

[0009] According to the present invention, it is possible to provide an immunological analysis method using a monoclonal antibody and a kit containing a monoclonal antibody that can analyze ICTP without requiring special facilities. [Brief explanation of the drawing]

[0010] [Figure 1] This figure shows the amino acid sequence of the peptide used as an immunogen. [Figure 2] This is a schematic diagram showing the amino acid sequences of each of the multiple peptides used in the epitope analysis. [Figure 3] This figure shows the reactivity of each obtained monoclonal antibody to the synthetic peptide (N-terminus). [Figure 4] This figure shows the reactivity of each obtained monoclonal antibody to the synthetic peptide (C-terminus). [Figure 5] This is a schematic diagram showing the relationship between the epitope sequence of each obtained monoclonal antibody and the amino acid sequence of the peptide used as the immunogen. [Figure 6]A graph showing the test results of the reactivity between the S25206 antibody and a biological sample (serum from cancer bone metastasis patients) by competitive ELISA. [Figure 7] A graph showing the test results of the reactivity between the S25207 antibody and a biological sample (serum from cancer bone metastasis patients) by competitive ELISA. [Figure 8] A graph showing the evaluation results of the correlation between the immunological analysis method using the S25207 antibody and the prior art pyridinoline ICTP reagent.

Mode for Carrying Out the Invention

[0011] 1. Immunological analysis method for C-terminal telopeptide of type I collagen in biological samples (Biological sample) The "biological sample" in the present invention mainly includes solid tissues and body fluids derived from a living body (organism), and it is preferable to use body fluids. The biological sample in the present invention is more preferably blood, serum, plasma, urine, saliva, sputum, tears, ear discharge, or prostatic fluid, and even more preferably blood, serum, or plasma. The blood, serum, or plasma can be the blood, serum, or plasma of a subject suffering from breast cancer, prostate cancer, or lung cancer. The blood, serum, or plasma can be the blood, serum, or plasma of a subject suffering from breast cancer, prostate cancer, or lung cancer and having bone metastasis of the cancer. In this specification, "bone metastasis" means that cancer occurring outside the bone metastasizes to the bone. The subject from which the biological sample is collected includes humans and animals (e.g., monkeys, dogs, cats, mice, guinea pigs, rats, and hamsters), and preferably humans. The biological sample can be the biological sample itself from the subject, or the one obtained by performing treatments such as dilution and concentration usually performed on the collected biological sample. Note that the person who collects and prepares the biological sample derived from the subject used in the present invention may be the same person as the person who performs the immunological analysis method of the present invention, or a different person. Also, the biological sample used in the present invention may be collected or prepared at the time of implementing the present invention, or may be collected or prepared in advance and stored.

[0012] (Type I collagen C-terminal telopeptide) Type I collagen C-terminal telopeptide (hereinafter sometimes referred to as ICTP) is a peptide produced during the degradation process of type I collagen, the main component of bone matrix. Type I collagen is formed by the aggregation of two α1 chains (type I) and one α2 chain (type I). The telopeptides at the N-terminus or C-terminus of the α1 or α2 chain are crosslinked with pyridinoline or deoxypyridinoline to form the structure of collagen fibers. When type I collagen is degraded by bone resorption, the telopeptide portion is released into the bloodstream as fragments while remaining crosslinked. On the other hand, the pyridinoline-crosslinked fragments containing the C-terminus are called type I collagen C-terminal telopeptides. ICTP is one of the bone resorption markers. Blood ICTP levels are significantly higher in cases of bone metastases from malignant tumors, particularly breast cancer, prostate cancer, or lung cancer, compared to cases without bone metastases. Therefore, it is considered useful as an aid in the diagnosis of bone metastasis in malignant tumors or as an indicator of treatment effectiveness.

[0013] (Monoclonal antibody) In this specification, "monoclonal antibody" means an antibody or antibody molecule obtained from a clone derived from a single antibody-producing cell. That is, in this specification, "monoclonal antibody" includes a fragment having the function of the monoclonal antibody, to the extent that the effects of the present invention are obtained. For example, examples of a fragment having the function of a monoclonal antibody include a functional fragment containing the Fab portion of the monoclonal antibody obtained by enzymatic digestion of the monoclonal antibody, a functional fragment containing the Fab portion of the monoclonal antibody produced by genetic recombination, and a functional fragment containing scFv produced by phage display. In this specification, "monoclonal antibody" refers to, for example, IgG, IgE, IgM, IgD, or IgA.

[0014] (Amino acid sequence shown in Sequence ID No. 1) The monoclonal antibody used in the immunological analysis method of the present invention is a monoclonal antibody that recognizes the amino acid sequence represented by GFDFSFLP (SEQ ID NO: 1) as an epitope (hereinafter sometimes referred to as the monoclonal antibody of the present invention). Preferably, the monoclonal antibody of the present invention is a monoclonal antibody that specifically recognizes the amino acid sequence represented by GFDFSFLP (SEQ ID NO: 1). "Specifically recognizes the amino acid sequence represented by GFDFSFLP (SEQ ID NO: 1)" means that it does not substantially bind to or react with peptide fragments having amino acid sequences other than GFDFSFLP (SEQ ID NO: 1). In this case, "peptide fragments having amino acid sequences other than GFDFSFLP (SEQ ID NO: 1)" includes peptide fragments in which a part of the amino acid sequence overlaps with GFDFSFLP (SEQ ID NO: 1) (for example, FDFSFLP (SEQ ID NO: 2)). The monoclonal antibody of the present invention preferably does not recognize the amino acid sequence represented by FDFSFLP (SEQ ID NO: 2) as an epitope. Therefore, the monoclonal antibody of the present invention preferably does not substantially bind to a peptide fragment consisting of the amino acid sequence represented by FDFSFLP (SEQ ID NO: 2). The monoclonal antibody of the present invention more preferably does not recognize either the amino acid sequence represented by FDFSFLP (SEQ ID NO: 2) or SAGFDFSFL (SEQ ID NO: 3) as an epitope. Therefore, the monoclonal antibody of the present invention more preferably does not substantially bind to either the peptide fragment consisting of the amino acid sequence represented by FDFSFLP (SEQ ID NO: 2) or SAGFDFSFL (SEQ ID NO: 3). The monoclonal antibody of the present invention may be S25207 antibody or S25210 antibody. The monoclonal antibody of the present invention may be S25207 antibody.

[0015] The inventors of the present invention have discovered that the concentration of ICTP in the blood can be measured by using the monoclonal antibody of the present invention. Furthermore, the inventors discovered that this monoclonal antibody does not recognize either the amino acid sequence represented by FDFSFLP (SEQ ID NO: 2), which is obtained by removing the first amino acid "G" at the N-terminus of GFDFSFLP (SEQ ID NO: 1), or SAGFDFSFL (SEQ ID NO: 3), which lacks the terminal amino acid "P" and has "SAG" added to the N-terminus, as epitopes. In addition, the inventors discovered that when using a monoclonal antibody that recognizes the amino acid sequence represented by SAGFDFS (SEQ ID NO: 4), which has an overlapping amino acid sequence with GFDFSFLP (SEQ ID NO: 1), as an epitope, it is not possible to measure the concentration of ICTP in the blood. It is surprising that a slight shift in the recognized amino acid sequence significantly affects the ability of monoclonal antibodies to measure blood ICTP concentration. While not limited to theory, the three-dimensional structure and characteristic sequences of the amino acid sequence around SEQ ID NO: 1 may be influencing recognition by monoclonal antibodies.

[0016] In this specification, the terms "reacts," "recognizes," and "binds" to a specific substance or amino acid sequence of a monoclonal antibody are used synonymously. Whether or not a monoclonal antibody "reacts" with an antigen (compound) can be confirmed by antigen-immobilized ELISA, competitive ELISA, or sandwich ELISA. Alternatively, it can be performed by methods utilizing the principle of surface plasmon resonance (SPR method). The SPR method can be performed using equipment, sensors, and reagents commercially available under the name Biacore®.

[0017] For example, when performing the same procedure as the competitive ELISA in the epitope analysis described later, if the signal is 70% or less (preferably 60% or less, more preferably 50% or less) compared to a control without added peptide, it can be evaluated that the monoclonal antibody recognized the amino acid sequence of the added peptide as an epitope.

[0018] (Method for preparing monoclonal antibodies) The monoclonal antibody of the present invention can be prepared by dissolving a peptide fragment of ICTP containing SEQ ID NO: 1, preferably a peptide fragment consisting of the sequence indicated by SAGFDFSFLFLPQPPQEKAHDGGRC (SEQ ID NO: 5), in a solvent such as phosphate-buffered saline, and administering this solution to a non-human animal for immunization. Alternatively, a peptide fragment that is metabolized in the animal to result in a peptide fragment consisting of the sequence indicated by SEQ ID NO: 5 may be administered. If necessary, an appropriate adjuvant may be added to the solution, and immunization may be performed using an emulsion. As an adjuvant, commonly used adjuvants such as water-in-oil emulsions, water-in-oil-in-water emulsions, oil-in-water emulsions, liposomes, and aluminum hydroxide gels may be used, as well as proteins or peptide substances derived from biological components. For example, Freund's incomplete adjuvant or Freund's complete adjuvant can be suitably used. The route of administration, dosage, and timing of administration of the adjuvant are not particularly limited, but it is desirable to select them appropriately so as to enhance the desired immune response in the animal being immunized with the antigen.

[0019] The type of animal used for immunization is not particularly limited, but mammals such as mice, rats, cattle, rabbits, goats, sheep, alpacas, or rats are preferred, and mice or rats are more preferably used. Immunization of animals can be carried out according to general methods, for example, by injecting a solution of antigen, preferably a mixture with an adjuvant, subcutaneously, intradermally, or intraperitoneally into the animal. Since the immune response generally differs depending on the type and strain of the animal being immunized, it is desirable to set the immunization schedule appropriately according to the animal being used. Antigen administration is preferably repeated several times after the initial immunization.

[0020] To obtain the monoclonal antibody of the present invention, the following operations may be carried out, but are not limited thereto. Since methods for producing the monoclonal antibody itself are well known and widely used in the art, those skilled in the art can prepare the monoclonal antibody of the present invention by using the aforementioned antigen (see, for example, Antibodies, A Laboratory Manual (Cold Spring Harbor Laboratory Press, (1988), Chapter 6, etc.)).

[0021] After final immunization, spleen cells or lymph node cells, which are antibody-producing cells, can be extracted from the immunized animals and fused with a myeloma-derived cell line having high proliferative capacity to produce hybridomas. It is preferable to use cells with high antibody-producing capacity (quality and quantity) for cell fusion, and it is even more preferable that the myeloma-derived cell line is compatible with the animal from which the antibody-producing cells to be fused originate. Cell fusion can be carried out according to methods known in the field. For example, the polyethylene glycol method, the Sendai virus method, or the electric current method can be employed. The resulting hybridomas can be grown according to conditions commonly used in this industry. The desired hybridomas can be selected while confirming the properties of the antibodies produced. Hybridoma cloning can be carried out by well-known methods such as the limiting dilution method or the soft agar method.

[0022] After the cloning process, the binding ability of the produced monoclonal antibody to the peptide fragment consisting of the amino acid sequence shown in SEQ ID NO: 1 can be assayed using methods such as ELISA, RIA, or immunofluorescence assay. The non-binding of the peptide fragment consisting of the amino acid sequence shown in SEQ ID NO: 2 or 3 may also be evaluated using a similar method. These operations allow for confirmation of whether the selected hybridoma produces a monoclonal antibody with the desired properties. By mass-culturing the hybridomas selected as described above, monoclonal antibodies with desired characteristics can be produced. The method of mass cultivation is not particularly limited, but examples include culturing hybridomas in a suitable culture medium to produce monoclonal antibodies in the medium, and injecting hybridomas into the peritoneal cavity of mammals to proliferate and produce monoclonal antibodies in the ascites fluid.

[0023] In addition to the entire antibody molecule, the monoclonal antibody of the present invention can also be a fragment of a monoclonal antibody having antigen-antibody reaction activity. Besides those obtained through the immunization process on animals as described above, monoclonal antibodies obtained using genetic engineering techniques, such as chimeric antibodies and humanized antibodies, can also be used. The monoclonal antibody fragment is preferably a functional fragment, such as F(ab')2, Fab', or scFv. These fragments can be prepared by treating the monoclonal antibody obtained as described above with a protease (e.g., pepsin or papain), or by cloning the DNA of the antibody and expressing it in a culture system using E. coli or yeast.

[0024] In the immunological analysis method of the present invention, a monoclonal antibody that recognizes an amino acid sequence in ICTP other than the amino acid sequence shown by GFDFSFLP (SEQ ID NO: 1) as an epitope (hereinafter sometimes referred to as a monoclonal antibody that recognizes a different amino acid sequence) can also be used. Such a monoclonal antibody that recognizes a different amino acid sequence can be easily prepared by those skilled in the art by making necessary modifications to the monoclonal antibody preparation method described above. Necessary modifications include, for example, the following. • Immunization with peptide fragments having amino acid sequences other than the amino acid sequence shown in GFDFSFLP (SEQ ID NO: 1) in ICTP, and • Assay the binding ability of a peptide fragment consisting of the amino acid sequence to be bound. When constructing the sandwich system described later, the monoclonal antibody that recognizes a different amino acid sequence is preferably a monoclonal antibody that recognizes an amino acid sequence that does not overlap with GFDFSFLP (SEQ ID NO: 1) as an epitope, taking into consideration the measurement principle of the sandwich system.

[0025] A sandwich system can also be constructed in immunological analysis methods using monoclonal antibodies that recognize different amino acid sequences. A sandwich system is a method that achieves high specificity and sensitivity by sandwiching the substance to be detected between two antibodies that recognize different epitopes.

[0026] In the sandwich method, one antibody is used as the solid-phase antibody, and the other antibody is used as the labeled antibody. In this specification, a solid-phase antibody means a monoclonal antibody immobilized on a solid phase. In this specification, a labeled antibody means a monoclonal antibody that is directly or indirectly labeled with a labeling substance that is well known and commonly used by those skilled in the art, as described later, when measuring the signal derived from the labeling substance. When constructing a sandwich system, it is preferable that at least one of the two monoclonal antibodies is a solid-phase antibody and at least one is a labeled antibody.

[0027] For example, solid-phase antibodies can be produced by physically adsorbing monoclonal antibodies onto a solid phase or by chemically binding them (perhaps via a suitable spacer). The solid phase can consist of polymer substrates such as polystyrene resin, inorganic substrates such as glass, or polysaccharide substrates such as cellulose or agarose. The shape of the solid phase is not particularly limited; any shape can be selected, such as a plate (e.g., microplate or membrane), beads or particulate matter (e.g., latex particles, magnetic particles), or a tube (e.g., test tube).

[0028] The amount of antibody bound to ICTP can also be measured by using a labeled antibody (secondary antibody) that can directly bind to the monoclonal antibody used in the immunological analysis method of the present invention. In this specification, an antibody bound to the monoclonal antibody of the present invention or a monoclonal antibody that recognizes another amino acid sequence, and to which a labeling substance is also bound, is referred to as a secondary antibody. This secondary antibody may be used to indirectly bind the labeling substance to the monoclonal antibody used in the immunological analysis method of the present invention.

[0029] The amount of ICTP in a biological sample can be measured by measuring the intensity of the signal emitted by the labeling substance. Examples of labeling substances for producing labeled antibodies include metal complexes, enzymes, insoluble particles, fluorescent substances, chemiluminescent substances, biotin, avidin, radioisotopes, gold colloid particles, or colored latex. Methods for conjugating the labeling substance to the monoclonal antibody include the glutaraldehyde method, maleimide method, pyridyl disulfide method, or periodic acid method, which are available to those skilled in the art. The types of solid-phase antibodies and labeled antibodies, as well as their manufacturing methods, are not limited to the examples given above. For example, when using an enzyme such as horseradish peroxidase (HRP) or alkaline phosphatase (ALP) as the labeling substance, the enzyme activity can be measured using the enzyme's specific substrate (for example, O-phenylenediamine (OPD) or 3,3',5,5'-tetramethylbenzidine (TMB) for HRP, or p-nitrophenyl phosphate for ALP). When biotin is used as a labeling agent, a monoclonal antibody can be labeled with biotin and reacted with avidin or streptavidin labeled with an enzyme, dye, or fluorescent label (preferably HRP). In the immunological analysis method of the present invention, it is preferable to use biotin or HRP as the labeling agent.

[0030] In this specification, the physical or chemical loading of antigens or antibodies onto a solid phase, or the state in which they are loaded, may be expressed as "immobilization" or "solid-phase loading." Furthermore, the terms "analysis," "detection," or "measurement" include proof of the presence of ICTPs and quantification of ICTPs.

[0031] In the immunological analysis method of the present invention, it is also possible to use only a monoclonal antibody that binds to one type of ICTP, that is, only the monoclonal antibody of the present invention. An example of such an analysis method is a competitive ELISA comprising the following steps (1) to (4). (1) Immobilize a peptide fragment containing the amino acid sequence shown in ICTP or SEQ ID NO: 1 onto a solid phase such as a microplate. (2) Add the biological sample to be analyzed to the microplate. (3) Add the enzyme-labeled monoclonal antibody of the present invention to a microplate. (4) Add the substrate to the enzyme and measure the signal derived from the enzymatic reaction. When competition occurs between ICTPs in a biological sample and ICTPs immobilized on a solid phase, the signal intensity decreases.

[0032] The immunological analysis method of the present invention can also use two types of monoclonal antibodies. The two types of monoclonal antibodies are the monoclonal antibody of the present invention and a monoclonal antibody that recognizes a different amino acid sequence in ICTP. When two types of monoclonal antibodies are used, the monoclonal antibody of the present invention is referred to as the first monoclonal antibody. The monoclonal antibody that recognizes a different amino acid sequence in ICTP is referred to as the second monoclonal antibody. Of the two types of monoclonal antibodies, at least one is a solid-phase antibody, and at least one is a labeled antibody. In this case, the immunological analysis method of the present invention can include the following steps (1) to (3). (1) Contact the biological sample with the first or second monoclonal antibody to form the first complex. The process, (2) The first complex and a first or second monoclonal antibody different from that of step (A) A step of bringing them into contact to form a second complex, (3) A step of measuring the signal originating from the labeled substance. The second complex contains a labeling substance. Depending on the labeling substance, a measurement method well known to those skilled in the art can be used to measure the signal.

[0033] When using one or two of the aforementioned monoclonal antibodies, the immunological analysis method of the present invention may optionally include a step of pre-treating the biological sample and / or a step of comparing the strength of the obtained signal with a first threshold. The first threshold can be set appropriately considering sensitivity and specificity. The first threshold may be a range. "The first threshold is a range" means that a specific threshold exists within the given range, and the presence or absence of disease is determined by whether the measured value is greater than or less than that specific threshold. For example, if the first threshold is in the range of 3 ng / mL to 6 ng / mL, and the specific threshold is 4 ng / mL to 6 ng / mL, then the specific thresholds could be 4.5 ng / mL, 5 ng / mL, 5.5 ng / mL, etc. Alternatively, the presence or absence of the disease may be determined by determining whether or not the value falls within a numerical range, for example, 4 ng / mL to 6 ng / mL, as described later in the "range threshold" method. The lower limit of the first threshold can be, for example, 0.1 ng / mL, 0.5 ng / mL, 1 ng / mL, 2 ng / mL, 3 ng / mL, 4 ng / mL, 4.5 ng / mL, 5 ng / mL, 6 ng / mL, 7 ng / mL, 8 ng / mL, 9 ng / mL, 10 ng / mL, 25 ng / mL, 50 ng / mL, or 100 ng / mL. The upper limit of the first threshold can be 100 ng / mL or less, 50 ng / mL or less, 25 ng / mL, 10 ng / mL, 9 ng / mL, 8 ng / mL, 7 ng / mL, 6 ng / mL, 5 ng / mL, 4.5 ng / mL, 4 ng / mL, 3 ng / mL, 2 ng / mL, 1 ng / mL, or 0.5 ng / mL. The specific first threshold ranges are 0.1 ng / mL to 100 ng / mL, 0.5 ng / mL to 50 ng / mL, 1 ng / mL to 10 ng / mL, 3 ng / mL to 6 ng / mL, and 4 ng / mL to 5 ng / mL. The first threshold may be a specific numerical value. Specific values ​​could be 4 ng / mL, 4.1 ng / mL, 4.2 ng / mL, 4.3 ng / mL, 4.4 ng / mL, 4.5 ng / mL, 4.6 ng / mL, 4.7 ng / mL, 4.8 ng / mL, 4.9 ng / mL, 5 ng / mL, 5.1 ng / mL, 5.2 ng / mL, 5.3 ng / mL, 5.4 ng / mL, 5.5 ng / mL, 5.6 ng / mL, 5.7 ng / mL, 5.8 ng / mL, or 5.9 ng / mL. The immunological analysis method of the present invention may include the steps of determining that breast cancer, prostate cancer, or lung cancer has metastasized to the bone if the signal strength is lower (higher) than a first threshold, or determining that breast cancer, prostate cancer, or lung cancer has not metastasized to the bone if the signal strength is higher (lower) than a first threshold.

[0034] The immunological analysis method of the present invention can determine the therapeutic effect of a specific drug (e.g., an antitumor agent) in patients with breast cancer, prostate cancer, or lung cancer based on the measured signal. In this case, the immunological analysis method of the present invention may further include the following steps in addition to the above steps. A process of administering a specific drug (e.g., an antitumor agent, etc.) to a subject, and / or A process of comparing the signal strength with a second threshold, In this case, the second threshold can be set appropriately considering sensitivity and specificity, but it may also be the measured value of ICTP in the subject before administering a specific drug (e.g., an antitumor agent) to the subject. The immunological analysis method of the present invention may include a step of determining that a particular drug (e.g., an antitumor agent) has a therapeutic effect if the signal strength is lower (higher) than a second threshold, or a step of determining that a particular drug (e.g., an antitumor agent) does not have a therapeutic effect if the signal strength is higher (lower) than a second threshold. Examples of the aforementioned antitumor agents include bisphosphonates, anti-RANKL antibodies (denosumab), RANKL antagonists (osteoprotegerin), and TGF-β kinase inhibitors (galunisertib). In determining the effectiveness of the treatment as described above, measurements may be taken every few days or weeks to monitor the treatment effect. The first and second thresholds may each take the form of "range thresholds." A "range threshold" is a method of determining the presence or absence of a disease not by comparing the measured value to a specific numerical value, but by determining whether the measured value falls within or outside a certain range.

[0035] (Immunological analysis method) Examples of immunological analytical methods of the present invention include, but are not limited to, electrochemiluminescence immunoassay (ECL), enzyme immunosorbent assay (ELISA), latex immunoturbidiometry (LTIA), chemiluminescence immunoassay, immunochromatography, and immunofluorescence assay. Preferably, the immunological analytical method of the present invention is electrochemiluminescence immunoassay, ELISA, latex immunoturbidiometry, or immunochromatography.

[0036] The immunological analysis method of the present invention can be an in vivo or in vitro immunological analysis method. Furthermore, a sensitizer may be used to enhance sensitivity. The immunological analysis method of the present invention can analyze ICTP present in a biological sample at concentrations of 0.1 ng / mL to 1 μg / mL, 0.2 ng / mL to 500 ng / mL, 0.3 ng / mL to 200 ng / mL, 0.5 ng / mL to 150 ng / mL, 1 ng / mL to 120 ng / mL, or 1 ng / mL to 100 ng / mL. In the immunological analysis method of the present invention, the order in which the monoclonal antibody of the present invention and the biological sample or type I collagen C-terminal telopeptide are added to the measurement system is not limited, as long as the effects of the present invention are obtained. That is, the monoclonal antibody of the present invention can be added to the measurement system before the addition of the biological sample or type I collagen C-terminal telopeptide, simultaneously with the addition of the biological sample or type I collagen C-terminal telopeptide, or after the addition of the biological sample or type I collagen C-terminal telopeptide. The following describes the measurement procedure and principle for each immunological analysis method employed. The following is merely an example of the measurement procedure and principle in one embodiment of the present invention and does not limit the scope of the present invention in any way. In each of the immunological analytical methods described below, specific methods such as the method for immobilizing the monoclonal antibody onto the solid phase, the method for binding the monoclonal antibody to the labeling substance, and the type of labeling substance may be those well known to those skilled in the art, including those mentioned above, without limitation. In the following example, the first monoclonal antibody is used as the solid-phase antibody and the second monoclonal antibody is used as the labeled antibody. However, the reverse configuration may be adopted as long as the effects of the present invention are obtained. That is, the first monoclonal antibody may be used as the labeled antibody and the second monoclonal antibody may be used as the solid-phase antibody.

[0037] (Electrochemiluminescence immunoassay) Electrochemiluminescence immunoassay is a method of measuring the amount of a substance to be detected by causing a labeled substance to emit light when an electric current is applied and detecting the amount of light emitted. In electrochemiluminescence immunoassay, a ruthenium complex can be used as the labeled substance. By placing an electrode on a solid phase (such as a microplate) and generating radicals on this electrode, the ruthenium complex is excited and emits light. The amount of light emitted by this ruthenium complex can then be detected. The measurement procedure and principle when using the first monoclonal antibody as the solid phase antibody, the second monoclonal antibody as the labeled antibody, magnetic particles as the solid phase, and a ruthenium complex as the labeling substance are as follows. (1) When magnetic particles immobilized with solid-phase antibodies are brought into contact with a biological sample, ICTP in the biological sample binds to the solid-phase antibodies. (2) When the magnetic particles are washed and then brought into contact with the labeled antibody, the labeled antibody binds to the ICTP that is bound to the magnetic particles. (3) After washing the magnetic particles, when electricity is applied, they emit light in proportion to the amount of labeled antibody bound to the ICTP. By measuring the amount of this light emission, the amount of the substance to be detected in the biological sample can be accurately measured.

[0038] (ELISA) Among immunological analytical methods, ELISA using enzyme labeling is preferred because it allows for simple and rapid measurement of the target. In this specification, ELISA refers to a method of detecting an antigen or antibody, which is a substance to be detected, contained in a sample, by capturing it using an antibody or antigen against the substance to be detected, and then detecting it using an enzymatic reaction. In the case of sandwich ELISA, either the first monoclonal antibody or the second monoclonal antibody may be used as the solid phase antibody. A plate (immunoplate) is preferred as the solid phase. HRP or ALP can be used as the label. The measurement procedure and principle when using sandwich ELISA as the immunological analytical method of the present invention are as follows. (1) When a biological sample is added to a solid phase on which a solid-phase antibody is immobilized and reacted, ICTP in the biological sample binds to the solid-phase antibody, forming a solid-phase antibody-ICTP complex on the solid phase. (2) When a labeled antibody that recognizes another labeled epitope is added to the solid phase and reacted, the labeled antibody binds to the captured ICTP and forms a sandwich with the solid-phase antibody-ICTP complex. (3) After washing, the enzyme reacts with the substrate, causing color development, and the absorbance is measured. The amount of ICTP in a biological sample can be measured according to the amount of labeling substance measured.

[0039] In the sandwich ELISA method, a secondary antibody can also be used. Using a secondary antibody amplifies the reaction and increases detection sensitivity. When using a secondary antibody, the following steps (1) to (4) can be adopted. (1) Primary monoclonal antibody as primary antibody, (2) A solid phase on which the second monoclonal antibody is immobilized, (3) An antibody against the primary monoclonal antibody labeled with an enzyme (such as HRP or ALP) (secondary antibody), and (4) Enzyme substrate (OPD, TMB, or p-nitrophenyl phosphate, etc.). First, a biological sample, appropriately treated and diluted, is added to a solid phase immobilized with a second monoclonal antibody, incubated, and then the biological sample is removed and washed. Next, the primary antibody is added, incubated and washed, and then the enzyme-labeled secondary antibody is added and incubated again. After that, the substrate is added and color development occurs. Subsequently, the amount of ICTP can be measured by measuring the color development using a plate reader or similar device.

[0040] Competitive ELISA, a competitive ELISA method, can also be employed. A competitive ELISA is a method for analyzing a substance to be detected in a biological sample by creating competition between the substance to be detected in the biological sample and a competing substance immobilized on a solid phase. Specifically, the following steps (1) to (4) can be used. (1) Immobilize a peptide fragment containing the amino acid sequence shown in ICTP or SEQ ID NO: 1 onto a solid phase such as a microplate. (2) Add the biological sample to be analyzed to the microplate. (3) Add the enzyme-labeled monoclonal antibody of the present invention to a microplate. (4) Add the substrate to the enzyme and measure the signal derived from the enzymatic reaction. Biotin can also be used. Streptavidin labeled with HRP or similar can be bound to this biotin. Then, the resulting color signal produced by adding OPD as a substrate can be measured.

[0041] (Latex immunoturbidimetry) Latex immunoturbidimetric analysis is an immunological analysis method that utilizes the agglutination of antibodies bound to the surface of latex with the substance to be detected (antigen). The latex particles used are not particularly limited, as long as they are those commonly used in in vitro diagnostic reagents. The concentration of latex particles and the average particle size of the latex particles during agglutination reaction measurement can be appropriately set according to the sensitivity or performance requirements. The measurement procedure and principle when using latex immunoturbidimetric analysis as the immunological analysis method of this invention are as follows. (1) The first monoclonal antibody and the second monoclonal antibody are bound to latex particles and brought into contact with the biological sample. (2) The ICTP in the biological sample binds to the first monoclonal antibody and the second monoclonal antibody, causing the antibody-bound latex particles to aggregate. (3) Irradiate the biological sample with near-infrared light and measure the absorbance or scattered light. Based on the measured values, the concentration of the antigen can be determined. In the immunological analysis method of the present invention, when latex immunoturbidimetry is used, the latex is both a solid phase and acts as a labeling substance. That is, both the first monoclonal antibody and the second monoclonal antibody are bound to the solid phase and the labeling substance, respectively.

[0042] (Immunochromatography) Immunochromatography is an immunological analysis method that utilizes the property of labeled antibodies bound to a substance to be detected, or the flow of labeled antibodies along a membrane. The general principle of measuring a substance to be detected in immunochromatography is as follows: An antibody against the antigen, which is the substance to be detected, is immobilized on an insoluble membrane support, which is the chromatographic medium, to create a detection unit, which is the stationary phase. Then, a labeled substance sensitized with an antibody capable of binding to the substance to be detected, which is the conjugate (detection reagent), is used as the mobile phase. The substance to be detected and the conjugate (mobile phase) are specifically reacted, and then, in the detection unit (stationary phase), the substance to be detected bound to the conjugate is specifically reacted with the antibody immobilized in the detection unit. The measurement procedure and principle when employing immunochromatography as the immunological analysis method of the present invention are as follows. (1) Bring the sample supply unit for supplying the biological sample into contact with the biological sample. (2) The ICTP in the biological sample comes into contact with the conjugate, and the first complex is formed. The conjugate is a labeling substance to which the first or second monoclonal antibody is bound. (3) The first complex comes into contact with the second or first monoclonal antibody immobilized on the detection unit, and the second complex is formed. (4) The formation of the second complex is confirmed by measuring the intensity of the signal originating from the labeling substance contained in the conjugate. Examples of labeling materials include gold colloid particles, platinum colloid particles, colored latex particles, and magnetic particles. The type and particle size of these labeling materials can be appropriately adjusted by those skilled in the art according to the desired sensitivity.

[0043] 2. Analysis kit for ICTP in biological samples The analysis kit for ICTP in biological samples of the present invention (hereinafter sometimes simply referred to as the analysis kit of the present invention) contains the monoclonal antibody of the present invention. The ICTP analysis kit of the present invention may be an analysis kit for a competitive method, preferably a competitive ELISA, comprising only the monoclonal antibody of the present invention. The analytical kit of the present invention can also use two types of monoclonal antibodies. These two types of monoclonal antibodies are the monoclonal antibody of the present invention and a monoclonal antibody that recognizes a different amino acid sequence. One can be a labeled antibody and the other a solid-phase antibody. In this case, the two types of monoclonal antibodies may be placed in separate containers.

[0044] Examples of analytical kits of the present invention include, but are not limited to, analytical kits for performing electrochemiluminescence immunoassay, ELISA, latex immunoturbidimetry, chemiluminescence immunoassay, immunochromatography, and immunofluorescence assay. Preferably, the analytical kit of the present invention is an analytical kit for performing electrochemiluminescence immunoassay, ELISA, latex immunoturbidimetry, or immunochromatography. The analytical kit of the present invention may be an analytical kit for analyzing in vivo or in vitro samples.

[0045] The analytical kit of the present invention may also include other test reagents such as standard antigens and quality control antigen samples, sample diluents, and / or instructions for use. The concentrations of reagents, including antibodies, can be adjusted as appropriate by those skilled in the art.

[0046] The reagents included in the kit are described below for each immunological analysis method used. In the following examples, the first monoclonal antibody is used as the solid-phase antibody and the second monoclonal antibody is used as the labeled antibody, but the reverse configuration may be used as long as the effects of the present invention are obtained.

[0047] When using electrochemiluminescence immunoassay, the analytical kit of the present invention may include (A) and (B) below. (A) A labeling reagent comprising a conjugate of a second monoclonal antibody and an electrochemiluminescent substance (e.g., a ruthenium complex), and (B) A solid phase on which the first monoclonal antibody that binds to ICTP is immobilized. For example, in a kit using magnetic particles as the solid phase, a biological sample is added to magnetic particles immobilized with a first monoclonal antibody that binds to ICTP and reacted with them. After the biological sample is removed and the mixture is washed, a conjugate is added and the mixture is reacted again. After washing the magnetic particles, electrical energy is applied to induce luminescence. Subsequently, ICTP can be analyzed by measuring the amount of luminescence emitted by the labeled substance.

[0048] When using a sandwich ELISA, the analytical kit of the present invention may include (A) and (B) below. (A) Labeling reagent containing a conjugate of a secondary monoclonal antibody and an enzyme (such as HRP or ALP) (B) Solid phase with the first monoclonal antibody immobilized. In this type of kit, first, a biological sample is added to a solid phase immobilized with the primary monoclonal antibody, incubated, and then the biological sample is removed and washed. Next, a labeling reagent is added and incubated, and then a substrate is added to induce color development. ICTP can be analyzed by measuring the color development using a plate reader or similar device.

[0049] In sandwich ELISA, a secondary antibody can also be used. By using a secondary antibody, the reaction can be amplified, and the detection sensitivity can be increased. When a secondary antibody is used, the analytical kit of the present invention may include the following (A) to (D). (A) Second monoclonal antibody as primary antibody (B) Solid phase with immobilized primary monoclonal antibody (C) An antibody against a secondary monoclonal antibody labeled with an enzyme (such as HRP or ALP) (secondary antibody) (D) Enzyme substrate (OPD, TMB, or p-nitrophenyl phosphate, etc.) In this type of kit, first, a biological sample, appropriately treated and diluted, is added to a solid phase immobilized with a primary monoclonal antibody, incubated, and then the biological sample is removed and washed. Next, the primary antibody is added and incubated and washed. Then, the enzyme-labeled secondary antibody is added and incubated again. After that, the substrate is added and color development occurs. ICTP can be analyzed by measuring the color development using a plate reader or similar device. The solid phase and the first monoclonal antibody may be included separately in the analysis kit. In this case, the person performing the analysis will immobilize the first monoclonal antibody onto the solid phase.

[0050] In the case of a competing ELISA, the analytical kit of the present invention may include (A) and (B) below. (A) A solid phase on which a peptide fragment containing the amino acid sequence shown in ICTP or SEQ ID NO: 1 is immobilized. (B) Monoclonal antibody of the present invention labeled with enzyme The solid phase and the peptide fragment containing the amino acid sequence indicated by ICTP or SEQ ID NO: 1 may be included separately in the analysis kit. In this case, the person performing the analysis will immobilize the peptide fragment containing the amino acid sequence indicated by ICTP or SEQ ID NO: 1 onto the solid phase. Biotin can also be used. The biotin may be bound to streptavidin labeled with HRP or the like. The substrate may further contain OPD.

[0051] When using latex immunoturbidimetry, the analytical kit of the present invention may include latex particles conjugated with a first monoclonal antibody and latex particles conjugated with a second monoclonal antibody. When using the latex immunoturbidimetry kit as the analytical kit of the present invention, the latex is both a solid phase and a labeling substance. Therefore, both the first monoclonal antibody and the second monoclonal antibody are conjugated to the solid phase and the labeling substance, respectively.

[0052] When using immunochromatography, the analytical kit of the present invention may be in the form of an immunochromatography test strip housed in a suitable container (housing). The immunochromatography test strip may consist of a sample pad having a sample supply section, an insoluble membrane carrier which is a chromatographic medium, and an absorption pad positioned at the downstream end of the insoluble membrane carrier. A detection section with a first monoclonal antibody immobilized on the insoluble membrane carrier may be placed on the insoluble membrane carrier, and a conjugate pad containing a conjugate may be placed between the sample pad and the insoluble membrane carrier. The conjugate may be contained on the sample pad or the insoluble membrane carrier. Other configurations of immunochromatography may be appropriately adopted, for example, those described in International Publication No. 2018 / 012517 or International Publication No. 2016 / 031892. Examples of labeling materials include gold colloid particles, platinum colloid particles, colored latex particles, and magnetic particles. The types and particle sizes of these labeling materials can be appropriately adjusted by those skilled in the art.

[0053] The above explanation is divided into aspects of the invention, but the matters, definitions of terms, and embodiments described in each aspect are also applicable to other embodiments. The present invention will now be specifically described with reference to examples, but these examples are not intended to limit the scope of the invention. Unless otherwise specified, % refers to mass %. [Examples]

[0054] <<Example 1: Preparation of Monoclonal Antibodies>> 1-1 Reagents and other materials used • Immunogens and antigens • Synthetic peptide (IC01:SAGFDFSFLPQPPQEKAHDGGRC (SEQ ID NO: 5)): Protein purification industry • Synthetic peptide (IC08:SAGFDFSFLPQPPQC (SEQ ID NO: 6)): Protein purification industry • Synthetic peptide (IC09:CSAGFDFSFLPQPPQ (SEQ ID NO: 7)): Protein purification industry • SM (PEG) 2,100 mg: Thermo, 22102 ·Albumin from bovine serum:Sigma,A7906-10G ·Transferrin,Human,recombinant:Wako,201-1808 ·Slide-A-Lyzer Dialysis Cassette(MWCO:10k):Thermo,66380

[0055] · SDS-PAGE Protein Transfer Kit: Cosmo Bio Co., Ltd., 423536 • Sample Treatment for Tris SDS: CosmoBio, 423420 ·Protein Multi Color Stable:Bio Dynamics Laboratory,DM660 Multi Gel II mini 4 / 20 (13W): Cosmo Bio, 414879 • TaKaRa CBB Protein Safe Stain (G250): Takara Bio, T9320A • Blocking solution, washing solution, substrate dissolving solution, and other reagents: in accordance with existing formulations.

[0056] ·Various ELISA • 96-well ELISA microplate: NUNC 442404 ·Goat anti-Mouse IgG(H+L)PAb-HRP:SouthernBiotech,1031-05,Lot F0415-NB76H ·Goat anti-Rat IgG (H+L)PAb-HRP:SouthernBiotech,3050-05,Lot G8212-PK14L ·anti-Human CTXI Mouse MAb:Cloud Clone,MAA665Hu21 • Washing solution, blocking reagent, OPD colorant, stop solution, etc.: In accordance with existing formulations.

[0057] • specimen • Serum from cancer patients with bone metastases, quantified using pyridinoline ICTP (Fujirebio (Orion Diagnostica)), was used.

[0058] • ICTP measurement reagents • Pyridinoline ICTP: Fujirebio (Orion Diagnostica)

[0059] 1-2 Preparation of immunogens The amino acid sequences of the immunogenic peptides used are shown in Figure 1. An SM(PEG)2 linker was used to crosslink the synthetic peptides with the carrier proteins. A 10 mg / mL carrier protein (BSA, HTF) solution was prepared using PBS as the solvent. More than 60 equivalents of SM(PEG)2 linker were added, and the mixture was stirred in a rotator at room temperature for 30 minutes. After the reaction, the solution was dialyzed twice against 500 mL / sample of PBS (4°C, 1st 4h, 2nd overnight). 60 equivalents of the carrier-linker peptide were dissolved in 100 μL of PBS. An equivalent volume of the peptide solution was added to 100 μL of the carrier-linker solution. The mixture was stirred in a rotator at room temperature for 30 minutes. After the reaction, the solution was dialyzed twice against 500 mL / sample of PBS (4°C, 1st 4h, 2nd overnight).

[0060] 1-3 Antibody production The peptide conjugate IC01-(PEG)2-HTF was used as the immunogen. These immunogens were mixed 1:1 with Freund's Complete Adjuvant (Difco Laboratories) for the first immunization and with Freund's Incomplete Adjuvant (Difco Laboratories) for subsequent immunizations. For Balb / c, 50 μg of immunogen was used for the first immunization, 20 μg for subsequent immunizations, and 50 μg (diluted with PBS) for the final immunization, and subcutaneous immunization was continued every two weeks. After three immunizations, serum antibody titers were evaluated by antigen-immobilized ELISA. For individuals in which a sufficient titer increase was confirmed, intraperitoneal immunization was performed with immunogen diluted with PBS 1-3 days before dissection. Subsequently, splenic cells, iliac lymph node cells, and inguinal lymph node cells were collected and fused with myeloma cells SP2 / 0 by electrofusion. The fused cells were cultured in 96-well plates. After collecting the culture supernatant 7 or 8 days after fusion, screening was performed using the antigen-immobilized ELISA method described below. Strains that were responsive to IC01-(PEG)2-BSA but not to Cys-(PEG)2-BSA were selected. The culture medium was changed the day before screening.

[0061] 1-4 Primary screening (antigen-immobilized ELISA) (1) IC01-(PEG)2-BSA and Cys-(PEG)2-BSA (1 μg / mL in PBS) were dispensed into a 96-well plate for ELISA (50 μL / well) and left to stand at room temperature for 2 hours. (2) After washing three times (400 μL / well), the blocking solution was dispensed (100 μL / well) and left to stand at room temperature for 1 hour or overnight at 4°C. (3) After removing the blocking solution, the cell culture supernatant (2-fold dilution) and antiserum (1000-fold and 10000-fold dilutions) were dispensed (50 μL / well) and left to stand at room temperature for 1 hour. (4) After washing three times, Goat anti-Mouse IgG(H+L)PAb-HRP (9500-fold dilution) was dispensed (50 μL / well) and left to stand at room temperature for 1 hour. (5) After washing three times, the OPD colorant was dispensed (50 μL / well) and left to stand at room temperature for 10 minutes. (6) Dispense the stop solution (50 μL / well), and after stopping the reaction, measure with a plate reader (Abs. 492 nm). (7) As a result, the S25206 antibody, S25207 antibody, S25209 antibody, and S25210 antibody were selected.

[0062] 1-5 Epitope Analysis Epitope analysis of acquired antibodies was performed using competitive ELISA with the peptide shown in Figure 2. (1) IC01-(PEG)2-BSA (10 ng / mL in PBS) was dispensed into a 96-well plate for ELISA (50 μL / well) and left to stand at room temperature for 2 hours. (2) After washing three times (400 μL / well), the blocking solution was dispensed (100 μL / well) and left to stand at room temperature for 1 hour or overnight at 4°C. (3) After removing the blocking solution, various peptides diluted with PBS (S25207 antibody: 1000 ng / mL, S25210 antibody: 200 ng / mL, S25206 antibody: 2 ng / mL, S25209 antibody: 313 ng / mL) were dispensed (25 μL / well), and then purified proprietary antibodies (S25207 antibody: 50 ng / mL, S25210 antibody: 10 ng / mL, S25206 antibody: 9 ng / mL, S25209 antibody: 14 ng / mL) were dispensed on top (25 μL / well), and the samples were left to stand at room temperature for 1 hour. (4) After washing three times, Goat anti-Mouse IgG(H+L)PAb-HRP (9500-fold dilution) was dispensed (50 μL / well) and left to stand at room temperature for 1 hour. (5) After washing three times, the OPD colorant was dispensed (50 μL / well) and left to stand at room temperature for 10 minutes. (6) Dispense the stop solution (50 μL / well), and after stopping the reaction, measure with a plate reader (Abs. 492 nm).

[0063] 1-6 Results of Epitope Analysis Figure 3 shows the results of investigating the N-terminal side of the amino acid sequence recognized as an epitope by acquired antibodies using various peptides. For S25206 and S25209 antibodies, reactivity to peptide IC13 was observed, while reactivity to peptides IC34, IC33, and IC36 was low. Therefore, the N-terminal side of the epitope for these antibodies was considered to be S. The S25207 and S25210 antibodies showed reactivity to peptides IC13, IC34, and IC35, but low reactivity to peptide IC36. Therefore, the N-terminal epitope of these antibodies was considered to be G. Similarly, Figure 4 shows the results of examining the C-terminal side of the amino acid sequence recognized as an epitope by the acquired antibody. For the S25206 antibody and S25209 antibody, reactivity to peptides IC31, IC14, IC32, and IC13 was observed, while low reactivity to peptide IC15 was shown. Therefore, the C-terminal side of the epitope for these antibodies was considered to be S. The S25207 and S25210 antibodies showed reactivity to peptide IC13, but low reactivity to peptides IC15, IC31, IC14, and IC32. Therefore, the C-terminal epitope of these antibodies was considered to be P. Based on the above, the epitopes of the S25206 antibody and the S25209 antibody were considered to be SAGFDFS (Sequence ID 4), and the epitopes of the S25207 antibody and the S25210 antibody were considered to be GFDFSFLP (Sequence ID 1) (Figure 5).

[0064] <<Example 2: Reactivity evaluation with actual samples using competitive ELISA>> Of the two monoclonal antibodies obtained in Example 1 that recognize different epitopes, the S25206 antibody and the S25207 antibody were used in the experiment.

[0065] 2-1 Operation of Competitive ELISA (1) IC01-(PEG)2-BSA (100 ng / mL in PBS) was dispensed into plates (50 μL / well) and left to stand at room temperature for 2 hours. (2) After washing three times (400 μL / well), the blocking solution was dispensed (100 μL / well) and left to stand at room temperature for 1 hour. (3) After removing the blocking solution, serum from cancer bone metastasis patients (5-10 dilutions, blank) was dispensed (25 μL / well), and then purified proprietary antibody (10 ng / mL in 1% BSA / PBST) was dispensed on top of that (25 μL / well), and the mixture was left to stand at room temperature for 1 hour. (4) After washing three times, Goat anti-Mouse IgG(H+L)PAb-HRP (9500-fold dilution) was dispensed (50 μL / well) and left to stand at room temperature for 1 hour. (5) After washing three times, the OPD colorant was dispensed (50 μL / well) and left to stand at room temperature for 10 minutes. (6) Dispense the stop solution (50 μL / well), and after stopping the reaction, measure with a plate reader (Abs. 492 nm).

[0066] 2-2 Results of Competitive ELISA For the S25206 antibody and the S25207 antibody, we evaluated their concentration-dependent reaction with ICTP in samples using competitive ELISA, with samples showing low (2.2 ng / mL) and high (76.8 ng / mL) ICTP levels. The results for the S25206 antibody are shown in Figure 6. The results for the S25207 antibody are shown in Figure 7. As a result, concentration-dependent reactivity was observed in both high- and low-level samples for the S25207 antibody. Concentration-dependent reactivity was not observed in either high- or low-level samples for the S25206 antibody. Therefore, it was demonstrated that the S25207 antibody binds to ICTP in the serum of patients with bone metastases from cancer.

[0067] <<Example 3: Correlation evaluation using competitive ELISA with the promising antibody S25207>> Regarding the S25207 antibody, 21 samples were measured using competitive ELISA, and their correlation with the original product was investigated.

[0068] 3-1 Operation of Competitive ELISA (1) IC01-(PEG)2-BSA (100 ng / mL in PBS) was dispensed into plates (50 μL / well) and left to stand at room temperature for 2 hours. (2) After washing three times (400 μL / well), the blocking solution was dispensed (100 μL / well) and left to stand at room temperature for 1 hour. (3) After removing the blocking solution, the original product standard (4-fold dilution, blank) and serum from cancer bone metastasis patients (4-fold dilution, blank) were dispensed (25 μL / well). Then, 8 ng / mL of biotinylated S25207 antibody was dispensed on top (25 μL / well), and the samples were left to stand at room temperature for 1 hour (0.1 mg / mL mouse IgG was used as a non-specific inhibitor). (4) After washing three times (400 μL / well), 0.2 μg / mL of HRP-Streptavidin was dispensed (50 μL / well) and allowed to stand at room temperature for 30 minutes. (5) After washing three times (400 μL / well), the OPD colorant was dispensed (50 μL / well) and left to stand at room temperature for 10 minutes. (6) Dispense the stop solution (50 μL / well), and after stopping the reaction, measure Abs. 492 nm with a plate reader.

[0069] 3-2 Results of Competitive ELISA A calibration curve was created from the measured values ​​of the original product standard, and the in-house measured value of the sample's ICTP was calculated based on the resulting regression equation. As a result, a good correlation was obtained with the original pyridinoline ICTP reagent (correlation coefficient r = 0.983) (Figure 8). [Industrial applicability]

[0070] According to the present invention, it is possible to provide an immunological analysis method using a monoclonal antibody and a kit containing a monoclonal antibody that can analyze ICTP without requiring special facilities. [Accession Number]

[0071] [Reference to deposited biological materials] (1) Hybridoma S25207 that produces antibody number S25207 (i) The name and address of the depositary institution that deposited the biological material. National Institute of Technology and Evaluation (NITE) 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (Postal Code 292-0818) Date of deposit of biological material with the depositary in Roy March 11, 2021 The depositary number assigned by the depositary in Hai to the deposit NITE BP-03431

Claims

1. An immunological analysis method for type I collagen C-terminal telopeptides in biological samples, This involves contacting the type I collagen C-terminal telopeptide with a monoclonal antibody that recognizes the amino acid sequence represented by GFDFSFLP (SEQ ID NO: 1) as an epitope. An immunological analysis method wherein the monoclonal antibody does not recognize the amino acid sequence represented by FDFSFLP (SEQ ID NO: 2) as an epitope.

2. The immunological analysis method according to claim 1, wherein the monoclonal antibody does not recognize the amino acid sequence represented by SAGFDFSFL (SEQ ID NO: 3) as an epitope.

3. The immunological analysis method according to claim 1 or 2, wherein a labeling substance is directly or indirectly bound to the monoclonal antibody.

4. The immunological analysis method according to claim 3, wherein the labeling substance is a metal complex, an enzyme, insoluble particles, or a metal colloid.

5. The immunological analysis method according to claim 3 or 4, further comprising the step of measuring a signal derived from the labeled substance.

6. The immunological analysis method according to any one of claims 1 to 5, wherein the biological sample is blood, plasma, or serum.

7. The immunological analysis method according to any one of claims 1 to 6, wherein the biological sample is a biological sample of a person suffering from breast cancer, prostate cancer, or lung cancer, and whose cancer has metastasized to the bone.

8. An immunological analysis method according to any one of claims 1 to 7, wherein the method is electrochemiluminescence immunoassay, latex immunoturbidimetry, immunochromatography, or ELISA.

9. A kit for the analysis of type I collagen C-terminal telopeptides in biological samples, It contains a monoclonal antibody that recognizes the amino acid sequence shown by GFDFSFLP (SEQ ID NO: 1) as an epitope. An analysis kit in which the monoclonal antibody does not recognize the amino acid sequence represented by FDFSFLP (SEQ ID NO: 2) as an epitope.

10. The analysis kit according to claim 9, wherein the monoclonal antibody does not recognize the amino acid sequence represented by SAGFDFFSFL (SEQ ID NO: 3) as an epitope.

11. The analytical kit according to claim 9 or 10, wherein the biological sample is blood, plasma, or serum.

12. The analysis kit according to any one of claims 9 to 11, wherein the biological sample is a biological sample from a patient who has breast cancer, prostate cancer, or lung cancer and has bone metastases.

13. An analytical kit according to any one of claims 9 to 12, for use in electrochemiluminescence immunoassay, latex immunoturbidimetry, immunochromatography, or ELISA.

14. A monoclonal antibody that recognizes the amino acid sequence represented by GDFSFLP (SEQ ID NO: 1) as an epitope, but does not recognize the amino acid sequence represented by FDFSFLP (SEQ ID NO: 2) as an epitope.

15. The monoclonal antibody according to claim 14, wherein the monoclonal antibody does not recognize the amino acid sequence represented by SAGFDFFSFL (SEQ ID NO: 3) as an epitope.

Images